Collaborative Arrangements and Licensing Agreements, GSK (Details) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2023 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2022 USD ($) Medicine	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue			$ 587,367	$ 810,456	$ 729,264
R&D Revenue [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue			$ 284,009	468,061	$ 364,565
GSK [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Number of medicines currently being developed | Medicine			2
Maximum amount of payments receivable over term of collaboration			$ 260,000
Maximum amount of license fees over term of collaboration			25,000
Maximum amount of development milestone payments over term of collaboration			42,500
Maximum amount of regulatory milestone payments over term of collaboration			120,000
Maximum amount of sales milestone payments over term of collaboration			70,000
Cumulative payments received			50,000
Next payment to be achieved			15,000
Revenue		$ 25,000
Deferred revenue			$ 0	$ 0
GSK [Member] | Revenue [Member] | Strategic Partner [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Concentration percentage			0.00%	0.00%	0.00%
GSK [Member] | Subsequent Event [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue	$ 15,000
GSK [Member] | R&D Revenue [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue			$ 0	$ 0	$ 200